Form D · Investing
Bioverge Funds, HepaTx I, LLC
Boise, ID · CIK 0001863964
Offering snapshot reported May 24, 2021 · SEC filing
- Reported sold
- $128K Offering amount: $150K
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $1.5K Reported outside-investor minimum
- First sale
- May 20, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 24, 2021 | Initial | $128,436 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Pooled investment fund
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-400369
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Bioverge Funds Management, LLC | None |
Source: Form D, filed May 24, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Neil Bioverge Funds Management, Llc Littman | Executive |
Issuer details
Industry: Investing (See others in industry)
Address:
222 N 13 Th St.
Boise, ID, 83702
Boise, ID, 83702